52 Week Range
As of on the XETRA ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
STADA Arzneimittel Announces Tender Offer Results
STADA Arzneimittel: Upcoming Expiration Of Tender Offer And Intention To Delist Notes
STADA Arzneimittel: Results Of Tender Offer
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products. The Branded Products segment focuses on multisource products accessible without active ingredient research, notably anti-enzymatic food intolerance drugs that are marketed by the subsidiary SCIOTEC Diagnostics Technologies. The Company's generic drugs are marketed by the Group subsidiary, STADApharm GmbH. Non-core activities of the Company encompass Commercial Business segment, which includes activities with primarily trading character such as wholesaling activities. The Company operates STADA Pharmaceuticals Australia Pty Ltd and STADA IT SOLUTIONS DOO as subsidiaries.
Biotechnology & Drugs
Chairman of the Executive Board
Guenter von Au
Independent Chairman of the Supervisory Board
Deputy Chairman of the Supervisory Board, Employee Representative
Chief Financial Officer, Member of the Executive Board
Managing Director of OTC segment
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
A top shareholder in German wind energy project developer PNE <PNEGn.DE> has called a non-binding bid from an infrastructure fund run by Morgan Stanley <MS.N> "completely inadequate", a letter seen by Reuters on Wednesday said.
German generic drugmaker Stada <STAGn.D> will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development deals with partners, the company's chief executive told Reuters.
German generic drugmaker Stada will be careful about buying businesses and companies outright, and for now will focus mainly on striking production and development deals with partners, the company's chief executive told Reuters.
Japan's Takeda Pharmaceutical Co <4502.T> has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters.
U.S. activist hedge fund Elliott Management announced on Thursday it had taken a 2.1% stake in German agrichemicals and pharma company Bayer <BAYGn.DE> Here are some of New York-headquartered Elliott's top holdings in Europe (in alphabetical order):
GlaxoSmithKline (GSK) has kicked off the sale of some consumer health brands as it seeks to raise about 1 billion pounds ($1.26 billion) before pressing ahead with a spinoff of its consumer healthcare business, sources told Reuters.
The following bids, mergers, acquisitions and disposals were reported by 2030 GMT on Friday:
Private equity-backed generic drugmaker Stada said on Friday it would buy six consumer healthcare products from British drugmaker GlaxoSmithKline to bolster its presence in Europe.
U.S. activist hedge fund Elliott Management announced on Wednesday that it had taken a 1.2 billion euro ($1.35 billion)stake in German technology company SAP <SAPG.DE>. [nL5N2260MG]
U.S. activist hedge fund Elliott Management announced on Wednesday that it had taken a 1.2 billion euro ($1.35 billion)stake in German technology company SAP.
* Taisho's sales of OTC drugs down year-on-year in April-Sept (Adds details on Taisho)
Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd <4581.T> is said to be close to a $1.6 billion deal for Bristol-Myers Squibb Co's <BMY.N> French over-the-counter drugs business UPSA, Bloomberg reported on Sunday, citing sources familiar with the matter.
U.S. activist hedge fund Elliott Management announced on Wednesday that it had taken a stake in French drinks maker Pernod Ricard <PERP.PA> worth more than 930 million euros ($1.05 billion).
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.